|
Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia. Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia. conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia. Clinical research trials and Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia. medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia.. Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia. Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia. clinical trial. Participants frequently obtain the most expert healthcare available for their Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia. condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia. Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia.
Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia.
For Condition: Pneumonia
Status: Completed
Sponsor(s): Pfizer ,
Synopsis: A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens. After written informed consent is obtained, patients will receive one of the following two treatment regimens: 1) intravenous administration of azithromycin and ceftriaxone followed by azithromycin tablets, or 2) intravenous administration of levofloxacin followed by levofloxacin tablets. At least four study visits are normally conducted up to approximately one month after starting therapy. The objective of this study is to compare the safety and efficacy of the two treatment regimens.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Patient must be 18 years or older. - Patient must be hospitalized and require intravenous therapy for treatment of pneumonia - Patient must have pneumonia as documented by relevant signs and symptoms and a positive chest X-ray. - Patients cannot have certain underlying diseases or conditions as defined in the study protocol.
Total Enrollment: 360
Location and Contact Information:
Pfizer Investigational Site
Regina, Saskatchewan, S4P 127
Canada
Pfizer Investigational Site
Philadelphia, Pennsylvania, 19140
United States
Pfizer Investigational Site
Halifax, Nova Scotia, B3H 3A7
Canada
Pfizer Investigational Site
Sellersville, Pennsylvania, 18960
United States
Pfizer Investigational Site
ROTENBURG, Niedersachen, D-27356
Germany
Pfizer Investigational Site
Royal Oak, Michigan, 48073
United States
Pfizer Investigational Site
Detroit, Michigan, 48202
United States
Pfizer Investigational Site
London, Ontario, N6A 4G5
Canada
Pfizer Investigational Site
Ottawa, Ontario, K1Y 4E9
Canada
Pfizer Investigational Site
Shawnee Mission, Kansas, 66204
United States
Pfizer Investigational Site
Sarasota, Florida, 34239
United States
Pfizer Investigational Site
St. Louis, Missouri, 63110
United States
Pfizer Investigational Site
Barcelona, , 08036
Spain
Pfizer Investigational Site
Long Beach, California, 90822
United States
Pfizer Investigational Site
Berlin, , D-14109
Germany
Pfizer Investigational Site
Louisville, Kentucky, 40202
United States
Pfizer Investigational Site
Ft. Gordon, Georgia, 30905
United States
Pfizer Investigational Site
LUEDENSCHEID, , 58515
Germany
Pfizer Investigational Site
Albuquerque, New Mexico, 87108
United States
Pfizer Investigational Site
Phenix City, Alabama, 36867
United States
Pfizer Investigational Site
Columbus, Georgia, 31904
United States
Pfizer Investigational Site
Winnipeg, Manitoba, R3A 1R9
Canada
Pfizer Investigational Site
Kirkwood, Missouri, 63122
United States
Pfizer Investigational Site
Saskatoon, Saskatchewan, S7L 2W1
Canada
Pfizer Investigational Site
ATHENS, , 15126
Greece
Pfizer Investigational Site
Montreal, Quebec, H1T 2M4
Canada
Pfizer Investigational Site
Tarrasa, CATALUNA, 08221
Spain
Pfizer Investigational Site
Hamilton, Ontario, L8V 1C3
Canada
Pfizer Investigational Site
San Antonio, Texas, 78229
United States
Pfizer Investigational Site
Winston Salem, North Carolina, 27103
United States
Pfizer Investigational Site
Saint-Nicolas, Quebec, G7A 2S2
Canada
Pfizer Investigational Site
Mineola, New York, 11501
United States
Pfizer Investigational Site
Cleveland, Ohio, 44106
United States
Pfizer Investigational Site
New York City, New York, 10003
United States
Pfizer Investigational Site
Sylmar, California, 91342
United States
Additional Information:
Study ID Numbers: A0661035;
Study Start Date:
Record last reviewed: November 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035347
Other Pneumonia Studies:
1. Tigecycline for the Treatment of Subjects with Selected Serious Infections Due to Resistant Gram-Negative Organisms
2. Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia.
3. Venticute in Patients with Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment
4. Tigecycline versus Imipenem/Cilastatin for the Treatment of Subjects with Nosocomial Pneumonia
5. Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients
Related Studies:
Other Pneumonia Clinical Trials
Other Manitoba Clinical Trials
Other Winnipeg Clinical Trials
Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia.
|
|
|
|
|
|
|
|